Opdivo + Yervoy receives Positive CHMP Opinion for colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. 

The opinion was based on data from the phase II CheckMate -142 trial. The European Commission, which is authorized to approve medicines for the European Union, will now review the CHMP recommendation.

Opdivo and Yervoy are sponsored by Bristol Myers Squibb.

YOU MAY BE INTERESTED IN

People of African ancestry (Black/African American) have some of the worst cancer incidence and greatest mortality, compared to white and other racial and ethnic populations in the U.S. On average, Black persons are 1.5 times more likely to have cancer and >2X more likely to die from cancer compared to whites. xxx:more

Login